DiclofenacThird Party Manufacturing in India

Diclofenac works by inhibiting the cyclooxygenase enzymes, specifically targeting both COX-1 and COX-2. It inhibits prostaglandin synthesis to help the body manage acute ocular inflammation and miosis during ophthalmic surgical interventions. Unlike corticosteroid alternatives, it controls ocular pain and inflammatory cascades without inducing steroid-related intraocular pressure spikes or secondary cataract formation. It is highly effective and well-tolerated when administered topically to the ocular surface.

Therapeutic Uses

• Postoperative Ocular Inflammation: Management of postoperative inflammation following cataract extraction and other ophthalmic surgeries.
• Ocular Pain Relief: Relief of pain, photophobia, and discomfort associated with corneal refractive surgery or accidental superficial ocular trauma.
• Miosis Prevention: Maintenance of intraoperative pupillary dilation during anterior segment ophthalmic procedures.

Why Manufacturers Choose Diclofenac

Diclofenac third party manufacturing in India has experienced sustained market growth due to the rising volume of cataract surgeries nationwide. Our partner facilities maintain WHO-GMP compliant manufacturing standards to ensure the production of completely sterile, irritation-free ophthalmic formulations with verified chemical stability. Having access to strict WHO-GMP certified operations guarantees the lowest particulate levels required for commercial success. This established formulation represents a stable revenue stream for distribution networks seeking reliable third-party supply lines.